Literature DB >> 25090603

Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making.

Ian M Thompson1, Robin J Leach1, Donna P Ankerst2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25090603      PMCID： PMC5015647          DOI： 10.1001/jama.2014.9680

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

3.  Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Authors:  Donna P Ankerst; Josef Hoefler; Sebastian Bock; Phyllis J Goodman; Andrew Vickers; Javier Hernandez; Lori J Sokoll; Martin G Sanda; John T Wei; Robin J Leach; Ian M Thompson
Journal:  Urology       Date:  2014-06       Impact factor: 2.649

4.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.

Authors:  Robert K Nam; Refik Saskin; Yuna Lee; Ying Liu; Calvin Law; Laurence H Klotz; D Andrew Loblaw; John Trachtenberg; Aleksandra Stanimirovic; Andrew E Simor; Arun Seth; David R Urbach; Steven A Narod
Journal:  J Urol       Date:  2013-01       Impact factor: 7.450

5.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

6.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

7.  Quality of life and satisfaction with outcome among prostate-cancer survivors.

Authors:  Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei
Journal:  N Engl J Med       Date:  2008-03-20       Impact factor: 91.245

8.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245
  9 in total
  16 in total

1.  The association between hypertension and prostate cancer.

Authors:  Shah Navin; Vladimir Ioffe
Journal:  Rev Urol       Date:  2017

2.  Prostate cancer: A traffic-stopping prediction tool?

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2014-08-26       Impact factor: 14.432

3.  Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

Authors:  Donna P Ankerst; Martin Goros; Scott A Tomlins; Dattatraya Patil; Ziding Feng; John T Wei; Martin G Sanda; Jonathan Gelfond; Ian M Thompson; Robin J Leach; Michael A Liss
Journal:  Eur Urol Focus       Date:  2018-02-13

4.  Evaluation of a pharmacogenetic educational toolkit for community pharmacists.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb
Journal:  Pharmacogenomics       Date:  2016-08-17       Impact factor: 2.533

5.  Assessment of men's risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer.

Authors:  Kevin Koo; Elias S Hyams
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

6.  Prostate cancer screening practices in a large, integrated health system: 2007-2014.

Authors:  Anita D Misra-Hebert; Bo Hu; Eric A Klein; Andrew Stephenson; Glen B Taksler; Michael W Kattan; Michael B Rothberg
Journal:  BJU Int       Date:  2017-02-26       Impact factor: 5.588

Review 7.  Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.

Authors:  Catherine M Tangen; Phyllis J Goodman; Cathee Till; Jeannette M Schenk; M Scott Lucia; Ian M Thompson
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

8.  Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.

Authors:  Donna Pauler Ankerst; Jonathan Gelfond; Martin Goros; Jesus Herrera; Andreas Strobl; Ian M Thompson; Javier Hernandez; Robin J Leach
Journal:  J Urol       Date:  2016-03-12       Impact factor: 7.450

9.  External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.

Authors:  Cédric Poyet; Marian S Wettstein; Dara J Lundon; Bimal Bhindi; Girish S Kulkarni; Karim Saba; Tullio Sulser; A J Vickers; Thomas Hermanns
Journal:  J Urol       Date:  2016-05-14       Impact factor: 7.450

10.  A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts.

Authors:  Donna P Ankerst; Johanna Straubinger; Katharina Selig; Lourdes Guerrios; Amanda De Hoedt; Javier Hernandez; Michael A Liss; Robin J Leach; Stephen J Freedland; Michael W Kattan; Robert Nam; Alexander Haese; Francesco Montorsi; Stephen A Boorjian; Matthew R Cooperberg; Cedric Poyet; Emily Vertosick; Andrew J Vickers
Journal:  Eur Urol       Date:  2018-05-16       Impact factor: 20.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.